<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="190706">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610428</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-001-201</org_study_id>
    <secondary_id>6 June 2005 Amendment</secondary_id>
    <nct_id>NCT00610428</nct_id>
  </id_info>
  <brief_title>Staccato Prochlorperazine in Patients With Migraine Headache</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of Staccato Prochlorperazine for the treatment of migraine headache.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient headache pain as measured on the scale: 0=NO headache pain, to 3=severe headache pain Measure: 1 = MILD headache pain Measure: 2 = MODERATE headache pain Measure: 3 = SEVERE headac</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Migraine Headache, With or Without Aura</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Staccato Prochlorperazine</intervention_name>
    <description>Low dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Staccato Prochlorperazine</intervention_name>
    <description>High dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Staccato Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have migraine headache with or without aura (diagnosis according to
             International Headache Society guidelines) for at least 6 months, who have been pain
             free for at least 48 hours since the end of their last migraine attack, who have a
             pain rating of Moderate or Severe prior to dosing.

        Exclusion Criteria:

          -  Subjects who have taken any other migraine or pain medication within 48 hours of
             randomization, with a history of allergy or intolerance to phenothiazines and related
             drugs, or are considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving prochlorperazine, or unable to use the inhalation device,
             must be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheena Auroa, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Roger K Cady, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Arthur Elkind, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Fred Freitag, DO</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Lisa Mannix, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Niana T Mathew, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Egilius LH Spierings, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Stewart Tepper, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Arthur H. Elkind, MD</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <lastchanged_date>January 28, 2008</lastchanged_date>
  <firstreceived_date>January 28, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Daniel A. Spyker, MD; Sr Director, Drug Safety &amp; Pharmacovigilance</name_title>
    <organization>Alexza Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>Migraine, Staccato Prochlorperazine</keyword>
  <keyword>Migraine headache with or without aura.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prochlorperazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
